Site Resource Centre
Xaluritamig is a novel T-cell engager immunotherapy being developed for advanced prostate cancer. Xaluritamig activates the immune system against prostate cancer cells by creating an immune synapse between immune T cells and STEAP1, a protein that is uniquely over-expressed in prostate cancer cells.1-3
The resources below are intended to support the XALute Study staff.